title: Lipid lowering and antioxidant effect of miglitol in triton treated hyperlipidemic and high fat diet induced obese rats.
abstract: Miglitol, an anti-diabetic drug, has been shown to reduce plasma lipids and inhibit free radical generation. The anti-hyperlipidemic and antioxidant effects of miglitol were studied in triton-induced hyperlipidemic rats and high fat diet-fed obese rats. Plasma cholesterol and triglycerides levels were significantly lowered by miglitol at 100 mg/kg body weight doses. Miglitol inhibited generation of superoxide anion and hydroxyl free radicals by 14 and 31 % in enzymatic systems and 19 and 25 % in non-enzymatic systems, respectively. The in-vitro effect of the drug on adipogenesis using 3T3-L₁ preadipocytes at 2-, 5- and 10-μM concentrations showed significant inhibition of adipogenesis (34.2 %) at 10-μM concentration. High fat diet-fed rat model was used to investigate anti-hyperlipidemic, anti-obesity and antioxidant effect of miglitol. Miglitol increased the activities of lecithin-cholesterol-acyltransferase (19 %), post heparin lipolytic activity (26 %), lipoprotein lipase (26 %) and triglyceride lipase (31 %) which result in a decrease in plasma lipid levels. The antioxidant enzymes viz., catalase, superoxide dismutase, glutathione peroxidase, glutathione reductase and thioredoxin reductase were increased by the drug in the treated animals. The antihyperlipidemic and antioxidant effect of miglitol can be correlated to its effect on different enzymes and it can be used for inhibiting the development of cardiovascular diseases.
authors: Biochemistry Division, CSIR-Central Drug Research Institute, 1 M.G. Marg, Lucknow 226001, India.
authors: Atul
authors: A
authors: Shrivastava
authors: Upma
authors: U
authors: Chaturvedi
authors: Shiv Vardan
authors: SV
authors: Singh
authors: Jitendra Kumar
authors: JK
authors: Saxena
authors: Gitika
authors: G
authors: Bhatia
mesh_terms: D017485:1-Deoxynojirimycin / Q000031:analogs & derivatives* / Q000494:pharmacology / Q000627:therapeutic use; D041721:3T3-L1 Cells; D050156:Adipogenesis / Q000187:drug effects; D000818:Animals; D000975:Antioxidants / Q000494:pharmacology / Q000627:therapeutic use*; D001835:Body Weight / Q000187:drug effects; D059305:Diet, High-Fat / Q000009:adverse effects; D004435:Eating / Q000187:drug effects; D006949:Hyperlipidemias / Q000097:blood / Q000139:chemically induced / Q000188:drug therapy* / Q000473:pathology; D007004:Hypoglycemic Agents / Q000494:pharmacology / Q000627:therapeutic use*; D008055:Lipids / Q000032:analysis / Q000097:blood; D008099:Liver / Q000187:drug effects / Q000378:metabolism / Q000473:pathology; D008297:Male; D051379:Mice; D009765:Obesity / Q000097:blood / Q000188:drug therapy* / Q000209:etiology / Q000473:pathology; D011092:Polyethylene Glycols; D051381:Rats
chemical_list: D000975:Antioxidants; D007004:Hypoglycemic Agents; D008055:Lipids; C045621:miglitol; D017485:1-Deoxynojirimycin; D011092:Polyethylene Glycols; C016811:tyloxapol